Autoimmune Diseases  >>  Plegridy (PEG-interferon β-1a)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Plegridy (PEG-interferon β-1a) / Biogen
NCT01337427: Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Withdrawn
3
0
US
BIIB017, PEGylated Interferon beta-1a, PEG IFN β-1a
Johns Hopkins University, Biogen
Relapsing Remitting Multiple Sclerosis
08/13
08/13
NCT01332019 / 2010-024477-39: Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

Checkmark ATTAIN
Apr 2015 - Apr 2015: ATTAIN
Checkmark AAN 2015: Multiple sclerosis (ATTAIN)
Mar 2015 - Mar 2015: AAN 2015: Multiple sclerosis (ATTAIN)
Checkmark ATTAIN
More
Completed
3
1077
US, Canada, Europe, RoW
peginterferon beta-1a, PEGylated Interferon beta-1a, Plegridy, PEG IFN β-1a, BIIB017
Biogen
Relapsing Multiple Sclerosis
10/15
10/15
NCT01939002: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

Checkmark ALLOW
Jun 2016 - Jun 2016: ALLOW
Completed
3
251
US
BIIB017, Plegridy, peginterferon beta-1a, PEGylated interferon beta-1a, PEG IFN β-1a, naproxen, naproxen sodium, Aleve, NSAID, long-acting nonsteroidal anti-inflammatory drug
Biogen
Relapsing Multiple Sclerosis
10/15
11/15

Download Options